Browsing Tag
Keith Rubin
1 post
hVIVO (AIM: HVO) wins world-first Phase III whooping cough challenge trial contract with ILiAD Biotechnologies
hVIVO (AIM: HVO) signs its largest human challenge trial contract with ILiAD Biotechnologies for a world-first pivotal Phase III pertussis vaccine study. Read what it means for investors.